Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.
Martín-Sánchez E, Blanco L, Kim PS, Bisht K, Wang H, Van de Velde H, Jelinek T, Simoes C, Prosper F, San Miguel JF, Alfonso A, Bergua J, Rodríguez-Veiga R, Vives S, Martínez-Cuadrón D, Montesinos P, Paiva B, Zabaleta A. Martín-Sánchez E, et al. Among authors: van de velde h. Blood Adv. 2024 Aug 13;8(15):3875-3879. doi: 10.1182/bloodadvances.2024013212. Blood Adv. 2024. PMID: 38815228 Free PMC article. No abstract available.
A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies.
Zabaleta A, Blanco L, Kim PS, Bisht K, Wang H, Van de Velde H, Lasa M, Tamariz-Amador LE, Rodriguez-Otero P, San-Miguel J, Paiva B, Martín-Sánchez E. Zabaleta A, et al. Among authors: van de velde h. Br J Haematol. 2024 Dec;205(6):2262-2267. doi: 10.1111/bjh.19784. Epub 2024 Sep 22. Br J Haematol. 2024. PMID: 39308023
Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities.
Bisht K, Merino A, Igarashi R, Gauthier L, Chiron M, Desjonqueres A, Smith E, Briercheck E, Romee R, Alici E, Vivier E, O'Dwyer M, van de Velde H. Bisht K, et al. Among authors: van de velde h. Exp Hematol Oncol. 2024 Nov 13;13(1):114. doi: 10.1186/s40164-024-00578-4. Exp Hematol Oncol. 2024. PMID: 39538354 Free PMC article. Review.
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
Kapoor P, Nathwani N, Jelinek T, Pour L, Perrot A, Dimopoulos MA, Huang SY, Spicka I, Chhabra S, Lichtman E, Mateos MV, Kanagavel D, Zhao L, Guillemin-Paveau H, Macé S, van de Velde H, Richardson PG. Kapoor P, et al. Among authors: van de velde h. Eur J Haematol. 2024 Nov;113(5):593-605. doi: 10.1111/ejh.14270. Epub 2024 Jul 12. Eur J Haematol. 2024. PMID: 38993150 Clinical Trial.
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.
Richardson PG, Perrot A, Mikhael J, Martin T, Beksac M, Spicka I, Capra M, D'Agostino M, Sonneveld P, Bisht K, Fukao T, Zhang R, Tada K, Tekle C, Macé S, Klippel Z, van de Velde H, Moreau P. Richardson PG, et al. Among authors: van de velde h. Blood Cancer J. 2024 Nov 28;14(1):209. doi: 10.1038/s41408-024-01149-w. Blood Cancer J. 2024. PMID: 39609425 Free PMC article. Clinical Trial.
Clinical pregnancy rates after blastocyst culture at a stable temperature of 36.6°C versus 37.1°C: a prospective randomized controlled trial.
Wouters K, Mateizel I, Segers I, Van de Velde H, Van Landuyt L, De Vos A, Schoemans C, Jankovic D, Blockeel C, Drakopoulos P, Tournaye H, De Munck N. Wouters K, et al. Among authors: van de velde h. Hum Reprod. 2024 Oct 1;39(10):2233-2239. doi: 10.1093/humrep/deae193. Hum Reprod. 2024. PMID: 39241807 Clinical Trial.
247 results